Sarepta Therapeutics: Navigating Elevidys Upside Potential (NASDAQ:SRPT)

17 min read


Link between genetics and various dystrophy disorders

Kagenmi/iStock via Getty Images

Thesis

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), submitted a request to the FDA aiming to erase the ambulation and age restrictions for Elevidys, as well as a switch in the designation from accelerated to standard approval. The company



Source link

You May Also Like

More From Author